Floatz logo

Vgn-R08B

Gaucher Disease Type 3

Shanghai Vitalgen BioPharma Co., Ltd.gene_therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Gaucher Disease Type 3 cohort.

Asset / SponsorPhaseRating
Velaglucerase Alfa
Baylor Research Institute
Phase 4BB
Cerezyme
Genzyme, a Sanofi Company
Phase 2CCC
Eliglustat
Genzyme, a Sanofi Company
Phase 2CCC
Venglustat
Genzyme, a Sanofi Company
Phase 2CCC

Same molecule, other indications

Vgn-R08B is also rated in:

Parkinson diseaseDormant
CC
Indicative ·
47 / 100
View asset →
Gaucher disease type IIDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →